Clobetasol Propionate 0.05% Lotion in the Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Evaluation versus Clobetasol Propionate Emollient Cream
May 2005 | Volume 4 | Issue 3 | Original Article | 330 | Copyright © May 2005
Debra Breneman MD, Alan B Fleischer Jr. MD, David Kaplan MD, Mark G. Lebwohl MD, Bruce Miller, MD, David Pariser, MD, Toivo Rist MD, L. Swinyer MDh, Yin Liu PhD, Valerie Foley PharmD
Abstract
Atopic dermatitis (AD) is a chronic inflammatory and pruritic skin disorder marked by alternating periods of
relapse and remission. This multicenter, randomized, active- and vehicle-controlled, investigator-blinded study
compared the efficacy and safety of clobetasol propionate lotion to clobetasol propionate cream formulation and
lotion vehicle in the treatment of moderate to severe AD. A total of 229 subjects applied treatment twice-daily
for 2 weeks. Clobetasol propionate lotion was significantly more effective than its lotion vehicle at 2 weeks and
comparable to the cream formulation. Clinical success after a 2-week, treatment-free follow-up period was greater
in the clobetasol propionate lotion group than in the cream group. Clobetasol propionate lotion is effective, safe,
well tolerated and offers a better remission profile in the treatment of moderate to severe AD as compared to clobetasol
propionate emollient cream.